Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound
Synopsis
The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.
Novo Nordisk AS (NVO) on Monday announced that it will offer its blockbuster obesity and diabetes drugs, Wegovy and Ozempic, for $199 a month to patients in the U.S. as it looks to take on rival Eli Lilly and Co.’s (LLY) Zepbound.
The Danish drugmaker announced that this offer is applicable to cash-pay patients looking to buy introductory doses of Wegovy and Ozempic. The company stated that patients can receive 0.25 mg and 0.5 mg doses of the two drugs for $199 per month for a period of two months. The offer is available from November 17, 2025, to March 31, 2026.
Novo Nordisk shares were down more than 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.